Dr Emily Sammons
BSc, MBChB, MSc
MRC PHRU Research Fellow
Dr Emily Sammons is a Clinical Research Fellow and DPhil student at the Clinical Trial Service Unit of the University of Oxford. She has particular research interests in diabetic eye disease and age-related macular degeneration. Alongside this she works on two large randomised controlled trials: ASCEND and REVEAL. ASCEND is studying whether aspirin and omega-3 fish oil supplementation protects against cardiovascular disease in people with diabetes. REVEAL is assessing the safety and benefits of taking a new lipid-modifying drug called anacetrapib, by those with pre-existing atherosclerotic vascular disease. Emily has background experience of working in General Medicine and a MSc in Public Health.
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.
HPS3/TIMI55–REVEAL Collaborative Group None. et al, (2017), N Engl J Med, 377, 1217 - 1227
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics.
REVEAL Collaborative Group None. et al, (2017), Am Heart J, 187, 182 - 190
Solitary metastasis of cervical carcinoma to the kidney: A case report and review of the literature
Hutchings DC. et al, (2009), UroToday International Journal, 2